2020
Prior history of acute pancreatitis predicts poor survival in patients with resectable pancreatic ductal adenocarcinoma
Gong Y, Fan Z, Luo G, Huang Q, Qian Y, Cheng H, Jin K, Ni Q, Yu X, Liu C. Prior history of acute pancreatitis predicts poor survival in patients with resectable pancreatic ductal adenocarcinoma. Pancreatology 2020, 20: 716-721. PMID: 32249060, DOI: 10.1016/j.pan.2020.02.016.Peer-Reviewed Original ResearchConceptsHistory of APPancreatic ductal adenocarcinomaResectable pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinoma patientsLog-rank testAcute pancreatitisSurgical resectionDuctal adenocarcinomaPoor survivalHazard ratioHistory of acute pancreatitisDiagnosis of pancreatic ductal adenocarcinomaAssociated with poor survivalIndependent survival predictorMultivariable-adjusted hazard ratiosKaplan-Meier methodRetrospective cohort studyCox proportional hazards modelsProportional hazards modelOverall survivalRemote historyClinical characteristicsCohort studyMultivariate analysisRisk factors
2016
Energy sources identify metabolic phenotypes in pancreatic cancer
Liang C, Qin Y, Zhang B, Ji S, Shi S, Xu W, Liu J, Xiang J, Liang D, Hu Q, Liu L, Liu C, Luo G, Ni Q, Xu J, Yu X. Energy sources identify metabolic phenotypes in pancreatic cancer. Acta Biochimica Et Biophysica Sinica 2016, 48: 969-979. PMID: 27649892, DOI: 10.1093/abbs/gmw097.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaWarburg phenotypeMetabolic phenotypeInducing different metabolic phenotypesCancer metabolic reprogrammingPancreatic ductal adenocarcinoma treatmentHallmarks of cancerStratified pancreatic ductal adenocarcinomaIndividual metabolic phenotypeMetabolic reprogrammingMetabolic pathwaysMetabolic typeDuctal adenocarcinomaMalignant tumorsHeterogeneous diseasePhenotypeTherapeutic approachesEnergy metabolismMetabolic featuresMetabolic diseasesMetabolic inhibitorsNutritional substratesMetabolite detectionDiseaseGlutaminolysisCritical role of oncogenic KRAS in pancreatic cancer (Review)
LIU J, JI S, LIANG C, QIN Y, JIN K, LIANG D, XU W, SHI S, ZHANG B, LIU L, LIU C, XU J, NI Q, YU X. Critical role of oncogenic KRAS in pancreatic cancer (Review). Molecular Medicine Reports 2016, 13: 4943-4949. PMID: 27121414, DOI: 10.3892/mmr.2016.5196.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaPancreatic cancerGenetically engineered mouse modelsPancreatic intraepithelial neoplasiaDevelopment of pancreatic ductal adenocarcinomaFormation of pancreatic intraepithelial neoplasiaProgression of pancreatic ductal adenocarcinomaIntraepithelial neoplasiaHigher mortality rateMutated KRASDuctal adenocarcinomaMouse modelHuman malignanciesKRASKRAS signalingPharmacological inhibitionOncogenic KRASPharmacological targetsMortality rateCancerTargeting KRASMolecular mechanismsProgression
2014
Metabolic tumour burden assessed by 18F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection
Xu H, Chen T, Wang W, Wu C, Liu C, Long J, Xu J, Zhang Y, Chen R, Liu L, Yu X. Metabolic tumour burden assessed by 18F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection. European Journal Of Nuclear Medicine And Molecular Imaging 2014, 41: 1093-1102. PMID: 24522797, DOI: 10.1007/s00259-014-2688-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntigens, Tumor-Associated, CarbohydrateCarcinoma, Pancreatic DuctalFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedMultimodal ImagingPancreatic NeoplasmsPositron-Emission TomographyPostoperative PeriodRadiopharmaceuticalsTomography, X-Ray ComputedTreatment OutcomeTumor BurdenConceptsSerum CA19-9 levelsRecurrence-free survivalMetabolic tumor volumeCA19-9 levelsMetabolic tumor burdenPancreatic ductal adenocarcinomaResectable pancreatic ductal adenocarcinomaTumor burdenOverall survivalTumor sizePancreatic ductal adenocarcinoma patientsSerum CA19-9Predicting overall survivalPancreatic cancer outcomesOperating characteristic analysisPredictive of outcomePET/CT examinationRadical pancreatectomyTumor volumeCA19-9Predicting OSSurrogate markerDuctal adenocarcinomaTLGMultivariate analysis